The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2017 | How important is understanding the tumour microenvironment in treating CLL?
Silvia Deaglio, MD, PhD, from University of Turin, Turin, Italy, discusses how the role of the tumour microenvironment in the progression and development of chronic lymphocytic leukemia (CLL) has now been well-established. She notes that this knowledge could be exploited therapeutically as many novel drugs for CLL now target the microenvironment, such as BTK inhibitors and BH3 mimetics, and these could prove to be a step forward in finding a cure for CLL. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
